Journal ArticleDOI
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Matthew G Krebs,Robert Sloane,Lynsey Priest,Lee Lancashire,Jian-Mei Hou,Alastair Greystoke,Timothy H Ward,Roberta Ferraldeschi,Andrew Hughes,Glen Clack,Malcolm R Ranson,Caroline Dive,Fiona H Blackhall +12 more
Reads0
Chats0
TLDR
CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease, and further validation is warranted before routine clinical application.Abstract:
Purpose Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy. Patients and Methods In this single-center prospective study, blood samples for CTC analysis were obtained from 101 patients with previously untreated, stage III or IV NSCLC both before and after administration of one cycle of standard chemotherapy. CTCs were measured using a semiautomated, epithelial cell adhesion molecule–based immunomagnetic technique. Results The number of CTCs in 7.5 mL of blood was higher in patients with stage IV NSCLC (n = 60; range, 0 to 146) compared with patients with stage IIIB (n = 27; range, 0 to 3) or IIIA disease (n = 14; no CTCs detected). In univariate analysis, progression...read more
Citations
More filters
Journal ArticleDOI
Integrating liquid biopsies into the management of cancer
TL;DR: How different forms of liquid biopsies can be exploited to guide patient care and should ultimately be integrated into clinical practice is examined, focusing on liquid biopsy of ctDNA — arguably the most clinically advanced approach.
Journal ArticleDOI
Challenges in circulating tumour cell research.
TL;DR: A conceptual framework of CTC assays is proposed and current challenges of C TC research are pointed out, which might structure this dynamic field of translational cancer research.
Journal ArticleDOI
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
Irène Baccelli,Andreas Schneeweiss,Sabine Riethdorf,Albrecht Stenzinger,Anja Schillert,Vanessa Vogel,Vanessa Vogel,Corinna Klein,Massimo Saini,Tobias Bäuerle,Markus Wallwiener,Tim Holland-Letz,Thomas Höfner,Martin R. Sprick,Martina Scharpff,Frederik Marmé,Hans-Peter Sinn,Klaus Pantel,Wilko Weichert,Andreas Trumpp +19 more
TL;DR: It is shown that primary human luminal breast cancer CTCs contain MICs that give rise to bone, lung and liver metastases in mice, and functional circulating MICs and associated markers are described to aid the design of better tools to diagnose and treat metastatic breast cancer.
Journal ArticleDOI
Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer
Jian Mei Hou,Matthew G Krebs,Lee Lancashire,Robert Sloane,Alison Backen,Rajeeb K. Swain,Lynsey Priest,Alastair Greystoke,Cong Zhou,Karen Morris,Timothy H Ward,Fiona H Blackhall,Caroline Dive +12 more
TL;DR: Molecular comparison of CTCs to cells in CTM may provide novel insights into SCLC biology and both baseline C TC number and change in CTC number after one cycle of chemotherapy are independent prognostic factors for SCLCs.
Journal ArticleDOI
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Cassandra L Hodgkinson,Christopher J. Morrow,Yaoyong Li,Robert Metcalf,Dominic G. Rothwell,Francesca Trapani,Radoslaw Polanski,Deborah J. Burt,Kathryn Simpson,Karen Morris,Stuart D Pepper,Daisuke Nonaka,Alastair Greystoke,Paul P. Kelly,Becky Bola,Matthew G Krebs,Jenny Antonello,Mahmood Ayub,Suzanne Faulkner,Lynsey Priest,Louise Carter,Catriona Tate,Crispin J. Miller,Fiona H Blackhall,Ged Brady,Caroline Dive +25 more
TL;DR: It is shown that CTCs from patients with either chemosensitive or chemorefractory SCLC are tumorigenic in immune-compromised mice, and the resultant CTC-derived explants (CDXs) mirror the donor patient's response to platinum and etoposide chemotherapy.
References
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.